Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8913SC

8913SC 10 µg (With Carrier)
8913SF 10 µg (Carrier Free)
8913LC 50 µg (With Carrier)
8913LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human PDGF-AA (hPDGF-AA) Ser87-Thr211 (Accession #NP_002598) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hPDGF-AA. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hPDGF-AA does not have a Met on the amino terminus and has a calculated MW of 14,305. DTT-reduced protein migrates as an 18 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 34 kDa protein. The expected amino-terminal SIEEA of recombinant hPDGF-AA was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hPDGF-AA was determined in a NIH/3T3 proliferation assay. The ED50 of each lot is between 4-12 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hPDGF-AA.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hPDGF-AA. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

PDGF-AA is integrally involved in embryonic development, angiogenesis and organogenesis and induces fibroblast proliferation and migration (1,2). PDGF-AA is produced by epithelial, muscle, osteosarcoma and neuronal progenitor cells (1,3). Active PDGF-AA is formed through intracellular proteolytic cleavage of a large precursor. PDGF-AA is also concentrated in the extracellular matrix through alternative splicing that generates an extended carboxy-terminal that binds components of the extracellular matrix. The carboxy-terminal stretch is removed extracellularly to generate mature PDGF-AA (1,2). PDGF-AA binding to the PDGFR-α activates the receptor tyrosine kinase (1). PDGF-AA-induced signaling is through the Ras-MAPK, PI3K/AKT and PLCγ pathways (1). Dysregulation of PDGF-AA expression and/or signaling is often associated with cancer and fibrotic disorders (1).


1.  Andrae, J. et al. (2008) Genes Dev 22, 1276-312.

2.  Hoch, R.V. and Soriano, P. (2003) Development 130, 4769-84.

3.  Siegbahn, A. et al. (1990) J Clin Invest 85, 916-20.


Entrez-Gene Id 5154
Swiss-Prot Acc. P04085


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.